Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma

CONCLUSIONS: The available evidence on the benefits and harms of CAR T-cell therapy for people with r/r DLBCL is limited, mainly because of the absence of comparative clinical trials. The results we present should be regarded in light of this limitation and conclusions should be drawn very carefully. Due to the uncertainty in the current evidence, a large number of ongoing investigations and a risk of substantial and potentially life-threatening complications requiring supplementary treatment, it is critical to continue evaluating the evidence on this new therapy.PMID:34515338 | DOI:10.1002/14651858.CD013365.pub2

Source: Cochrane Database of Systematic Reviews - September 13, 2021 Category: General Medicine Authors: Moritz Ernst Annika Oeser Burcu Besiroglu Julia Caro-Valenzuela Mohamed Abd El Aziz Ina Monsef Peter Borchmann Lise J Estcourt Nicole Skoetz Marius Goldkuhle Source Type: research